Compare Advanced Micro Devices (AMD) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advanced Micro Devices vs Moderna, Inc. — how do they compare? Advanced Micro Devices trades at $547.12 (market cap $909.70B), while Moderna, Inc. trades at $69.4 (market cap $27.09B). The key difference: Advanced Micro Devices is far larger — about 33.6× Moderna, Inc.'s market cap, and Advanced Micro Devices is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| AMD | MRNA | |
|---|---|---|
Market Cap | $909.70B | $27.09B |
Sector | Technology | Health |
52-Week High | $580.91 | $81.80 |
52-Week Low | $146.24 | $22.36 |
Enterprise Value | $901.22B | $23.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMD trades at $557.89, up 2.04% today and near its 52-week high, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth, with 2025 revenue reaching $34.64 billion and net income surging to $4.34 billion, though valuation ratios like P/E of 185.96 indicate premium pricing. Recent earnings beats and positive AI-driven news fuel investor optimism.
Outlook remains positive due to AI demand and earnings momentum, but high valuations and intense competition pose risks. Analyst consensus is strongly bullish with a $508.24 price target, though the stock trades above this, suggesting near-term caution amid long-term growth potential.
Moderna (MRNA) trades at $68.27, down 10.83% amid a biotech sell-off, but maintains a bullish technical trend with strong moving averages. Revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B, yet recent quarterly EPS beats and pipeline expansions into oncology and flu vaccines fuel optimism. The stock remains volatile, with a consensus price target of $49.00 below the current price, reflecting mixed analyst sentiment.
The outlook hinges on pipeline execution, with EU RSV vaccine contracts and FDA decisions offering upside, but high cash burn and competitive pressures pose risks. Investors face a trade-off between growth potential and profitability challenges, with the stock's 70% monthly surge testing sustainability near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
